Retension Pharmaceuticals
RTSN
Dilution Known so far: 3.8M possible new shares · no effective shelf · not yet read: warrants, converts, options, ATM. Every source
Every Retension Pharmaceuticals filing is below, newest first.
Insiders 2 insiders bought $370K of Retension Pharmaceuticals stock on the open market in the last 90 days. Every trade
IPO registration
Priced and listed · S-1/A filed Oct 7, 2026
- Final prospectus, offering priced 424B4
- Shares registered for exchange listing 8-A12B
- Registration declared effective EFFECT
- Amended registration S-1/A
- Amended registration S-1/AFirst filing
All filings
Results, 8-Ks and Major or Notable filings come first, then registrations and share actions, then everything else, newest first. Routine filings are kept here unmarked; insider filings are summed up in one line.
No RTSN filings found yet.
Possible new shares
Known so far: 3.8M possible new shares · no effective shelf · not yet read: warrants, converts, options, ATM.
- 3.8M new shares from the 424B4 of Oct 9, 2026
Not read yet: warrants, convertible notes, options and RSUs and an ATM program.
Listing compliance
No listing notices in the 8-K item 3.01 filings SEC Tracker has read.
Dates and rules are as stated in each 8-K item 3.01 filing; a blank means the filing did not state one. Read the filing for the full terms. All open notices
Trading halts
No trading halts for RTSN since Feb 22, 2019, when SEC Tracker began reading the Nasdaq Trader feed.
Halt times and codes from the Nasdaq Trader trade halts feed, which lists Nasdaq and other exchange halts. Filings matched by SEC Tracker from EDGAR by company and time. Not investment advice. All recent halts
Retension Pharmaceuticals shares and listing
From the company's own filings; each row names its source. Not investment advice.
- Listing compliance8-K item 3.01No noticesin the filings read
Insider activity
2 insiders bought $370K of Retension Pharmaceuticals stock on the open market in the last 90 days.
- CEO bought $250K
- Director bought $120K